Navigation Links
Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment
Date:10/19/2011

This release is available in Spanish.

Researchers from Massachusetts General Hospital, Harvard Medical School and CIC bioGUNE discover a complex cell mechanism activated by a protein HOXB9 that becomes an obstacle for radiation effectiveness.

Scientists all over the world continue to focus their research on breast cancer. As a consequence, knowledge of the behaviour of tumour cells is growing, as well as of their interactions with the microenvironment. There are, however, many questions still unanswered.

A new collaborative study carried out by the laboratory of Dr Mara Vivanco, researcher at the Cell Biology and Stem Cells Unit in the Center for Cooperative Research in Biosciences, CIC bioGUNE, and the groups led by Dr Zou and Dr Maheswaran in Boston, has provided insight into one of these mysteries: a cell mechanism that explains how a protein - called HOXB9 - helps cancer cells to avoid the attack of treatments such as radiation, and prevents the therapy from having the desired effect on certain types of breast cancer.

The study was recently published in Proceedings of the National Academy of Sciences (PNAS). The study shows that cells that express higher levels of the HOXB9 transcription factor are more likely to survive the radiation used as breast cancer treatment.

A complex mechanism induced by this protein has been discovered, which manages to activate a whole chain of cell processes in which different proteins - such as ATM kinase, amongst others - intervene, and which make certain cancerous cells more resistant to treatment. Dr Vivanco explains, "when the tumour is exposed to radiation it induces DNA damage a phenomenon that results in formation of double-stranded DNA breaks - leading the cells to respond and try to repair the damage caused in the DNA using another mechanism - called the DNA damage response," by activating ATM kinase. In this way, the cell cycle is stopped and the DNA is repaired in order to maintain chromosome stability.

HOXB9 expression causes an increase in survival of cells that have been exposed to radiation. This higher resistance occurs because of the acceleration of response to radiation and its higher recovery capacity after DNA damage. On the other hand, reduction of the levels of this protein, leads to increased cell sensitivity to radiation. Furthermore, the growth factor TGFbeta (a HOXB9 target) is also involved. Therefore, HOXB9 facilitates DNA repair by activation of the TGFbeta signalling pathway, which elevates ATM phosphorylation, accelerates DNA damage response and radiation resistance.

The published research is the continuation of another study carried out last year by CIC bioGUNE, Massachusetts General Hospital and Harvard Medical School, which showed that this same protein (HOXB9) is overexpressed in breast cancer and that its expression levels are associated with high tumour grade.


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
0034-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Penn receives $12.5 million from NIH to speed discovery to patient care
2. A*STAR scientists make headway for cancer treatment and cancer prevention with landmark discovery
3. New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery
4. Sweet insight: Discovery could speed drug development
5. URMC and Temple announce drug discovery partnership
6. Stanford discovery may eliminate potentially lethal side effect of stem cell therapy
7. Brain tumor discovery could lead to new treatment
8. Discovery of a new mechanism of gene control that is associated with cancer
9. Anti-cancer drug discovery partnership formed between UMMC and Ole Miss
10. Discovery of Lung Stem Cells May Herald New Treatments
11. Discovery could change the way doctors treat patients with cancer and autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... 2017 , ... Preora Diagnostics Inc. , a privately ... received two prestigious recognitions that acknowledge the promise of its PWS Nanoctyology platform ... been named a Top 100 Finalist for the 16th annual Chicago Innovation Awards ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that specializes ... to the athletic wear market with the launch of their FlipBelt Crops. , The ... essentials securely at their fingertips while at the gym, on the trail, or on-the-go. ...
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... Virginia (PRWEB) , ... September 20, 2017 , ... ... Flex Pure Clinical Plus Coating System for clients that rely on safety and ... the growth of microorganisms. , Silver has been used for centuries for its ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Doctors on ... to their qualified network of medical professionals working on a personal injury lien basis. ... Spine Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: